Assessing BioNTech: Insights From 11 Financial Analysts
Assessing BioNTech: Insights From 11 Financial Analysts
評估 BioNTech：來自 11 位金融分析師的見解
Ratings for BioNTech (NASDAQ:BNTX) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去三個月中，11位分析師提供了BioNTech（納斯達克股票代碼：BNTX）的評級，顯示了看漲和看跌的觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表總結了他們最近的評估，說明了過去30天不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $130.82, a high estimate of $171.00, and a low estimate of $90.00. Witnessing a positive shift, the current average has risen by 4.66% from the previous average price target of $125.00.
分析師通過對12個月目標股價的評估提供了更深入的見解，顯示平均目標價爲130.82美元，最高估計爲171.00美元，低估值爲90.00美元。當前的平均價格從之前的平均目標價125.00美元上漲了4.66％，這是一個積極的轉變。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
The standing of BioNTech among financial experts is...
通過對近期分析師...
登入免費觀看全文
登入/註冊